Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new vaginal scanner map tumors and cut MRI reliance?

NCT ID NCT07818850

Diagnosis Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 18, 2026 · Updated 3 times

Summary

Researchers at University Health Network in Toronto are testing a device called Vagina-View to see if it can clearly show vaginal tumor tissue and help position a brachytherapy applicator during treatment for vaginal cancer. Ten participants with gynecological cancer who are scheduled for MRI-guided brachytherapy will have the device placed in the vagina for about 10 to 15 minutes during each imaging session. The device is used only for imaging, not for treatment planning or delivery, and the study compares what it sees against standard MRI scans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vagina-View device, a vaginal imaging applicator used during brachytherapy
What this could lead to
If it works, the device could help doctors place brachytherapy applicators more precisely and rely less on MRI, which may spare healthy tissue and lower costs.
What could go wrong
This is a small, early feasibility study with 10 participants, so it cannot prove the device improves treatment outcomes. The device is not used for actual treatment planning in this study, and results may not apply to other brachytherapy devices or centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any patient with gynecological cancer who is planned to receive MRI-guided intravaginal brachytherapy with an MCA applicator. * Able to receive and understand verbal and written information regarding study and able to give written informed consent Exclusion Criteria: * Patient receiving brachytherapy with a different brachytherapy device. * Patient with contraindications to MRI.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vaginal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vaginal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vaginal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Princess Margaret Cancer Centre

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.